Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SIGLEC5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIGLEC5 ECD-Fc Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). HEK293 Expressed for native glycosylation. Sequence Verified. |
View SIGLEC5 Products |
| Gene Delivery | SIGLEC5 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based binding assays. |
View SIGLEC5 Products |
| Benchmark Ab | Anti-SIGLEC5 Recombinant Antibody Recombinant positive control derived from public therapeutic sequences. |
View SIGLEC5 Products |
| Validator | SIGLEC5 siRNA Set Target-specific siRNA pool for knockdown verification in primary myeloid cells. |
View SIGLEC5 Products |
| Related Target A | SIGLEC14 Highly homologous activating receptor (paired receptor with SIGLEC5). Crucial for counter-screening to ensure therapeutic selectivity. |
View SIGLEC14 Products |
| Related Target B | SIGLEC9 Co-expressed inhibitory myeloid checkpoint. Targeted synergistically in pan-Siglec tumor immunology programs. |
View SIGLEC9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SIGLEC5 vs. SIGLEC14 Selectivity Screening | HEK293-expressed SIGLEC5 and SIGLEC14 proteins available with strict sequence verification and >95% purity to resolve high-homology cross-reactivity. |
| Conformation-dependent Antibody Binding | Lentiviral vectors optimized for high-expression stable host cell lines to preserve native multi-pass or complex membrane topology. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SIGLEC5/CD170 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SIGLEC5 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific myeloid checkpoint inhibitors. As first-generation immunotherapies reach their efficacy ceilings, the next wave of R&D is targeting the sialic acid-Siglec pathway to reprogram tumor-associated macrophages (TAMs) and suppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Innate Pharma, Alector | Solid Tumors, Neurodegenerative Diseases | Ligand-blocking assays (Requires highly purified, glycosylated SIGLEC5 ECD-Fc) |
| Bispecific / Multi-specifics | Biotech Consortia | Refractory Solid Tumors | Selectivity profiling (Requires SIGLEC5 vs. SIGLEC14 counter-screening panel) |
| Sialidase Fusions (Eagle) | Palleon Pharmaceuticals | Immunotherapy-resistant Cancers | Enzymatic cleavage assays (Requires sequence-verified target proteins) |